Live bacterial therapeutics (LBTs) that engraft in the gut and provide persistent beneficial functions to the host have emerged as a promising strategy against a wide range of diseases.

Protein functional sites usually include a small number of residues that are crucial for binding or catalytic functions. One approach for the design of proteins with new functions consists of designing an amino acid sequence that folds up to a 3D structure containing the site, given a functional site description from any source.

Ozette Technologies has announced USD 26 million in Series A funding. The company is focused on artificial intelligence (AI)-powered single-cell immune discovery technology.